Higher dose of burosumab is needed for treatment of children with severe forms of X-linked hypophosphatemia
1APHP, Reference Center for Rare Disorders of the Calcium and Phosphate Metabolism, Filiere OSCAR and Platform of Expertise for Rare Diseases Paris-Sud, Bicêtre Paris-Sud Hospital, Le Kremline Bicetre, France; 2Department of Clinical Medicine and Surgery, Division of Endocrinology, University of Naples Federico II, Naples, Italy; 3Paris Sud Paris Saclay University, Faculté de Médecine, Le Kremlin- Bicêtre, France; 4APHP, Department of Endocrinology and Diabetology for children, Bicêtre Paris Sud Hospital, Le Kremlin- Bicêtre, France; 5APHP, Department of Endocrinology and Reproductive Diseases, Bicêtre Paris Sud Hospital, Le Kremlin- Bicêtre, France; 6APHP Department of Pediatric Radiology, Bicêtre Paris Sud Hospital, Le Kremlin- Bicêtre, France; 7APHP Department of ORL, Bicêtre Paris Sud Hospital, Le Kremlin- Bicêtre, France; 8Department of Odontology-Maladies Rares, Hospital Bretonneau, Paris, France; 9Université Paris Descartes, Paris, France; 10Department of Pediatric orthopaedic surgery, Necker - Sick Kids University Hospital, Paris, France; 11APHP, Department of Rheumatology Hospital Cochin, Paris, France; 12Pediatric Neurosurgery, Hospital Femme Mere Enfant, Hospices Civiles de Lyon and University Claude Bernard Lyon, Bron Cedex, France; 13Reference Center for Craniosynostosis, INSERM 1033, Lyon, France; 14APHP, Department of Molecular Genetics, Pharmacogenetics and Hormonology, Bice^tre Paris-Sud Hospital, Le Kremlin Bicêtre, France; 15Université Paris V, Faculté de Médecine, Paris, France; 16Hôpital Necker Enfants Malades APHP, INSERM U1151, Paris, France.
ba0007p51